Serum Biomarkers for Inflammatory Bowel Disease

Area of Science:

• Gastroenterology
• Biomarker Research
• Immunology

Background:

• Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, is a chronic gastrointestinal inflammatory condition.
• Accurate disease assessment and prediction of therapeutic response are critical challenges in IBD management.
• There is a growing need for convenient, economical diagnostic and clinical assessment methods due to rising IBD incidence.

Purpose of the Study:

• To review existing data on serological biomarkers for inflammatory bowel disease (IBD).
• To explore the role of serum biomarkers in IBD diagnosis, treatment efficacy evaluation, disease activity surveillance, and prognosis assessment.

Main Methods:

• A literature search was conducted on PubMed using specific keywords related to serum biomarkers in IBD.
• The review focused on studies concerning diagnosis, therapeutic efficacy, disease activity, and prognosis of IBD.

Main Results:

• Established biomarkers like C-reactive protein were reviewed.
• Newly discovered biomarkers including cytokines, antibodies, and non-coding RNAs were examined.
• Recent advancements such as metabolomics and proteomics in IBD management were also discussed.

Conclusions:

• Currently, no single ideal serum biomarker for IBD has been identified.
• Serum profiling and non-coding RNAs demonstrate significant potential for future clinical use in IBD.
• Combining multiple biomarkers may enhance the accuracy of IBD evaluation.